ESSA Pharma Inc. Acquisition by Xeno Acquisition Corp.

ESSA Pharma Inc. was acquired by Xeno Acquisition Corp. on October 9, 2025, through an arrangement under Section 288 of the Business Corporations Act (British Columbia). The acquisition involved XenoTherapeutics, Inc., XOMA Royalty Corporation, and a wholly-owned subsidiary of XenoTherapeutics, Inc. The transaction resulted in the exchange of all outstanding common shares of ESSA Pharma Inc. for $0.124231 in cash per share and one contingent value right per share, which could potentially yield up to $0.14 per share. As a result of this acquisition, the reporting persons, including Biotechnology Value Fund L P and related entities, ceased to beneficially own any securities of ESSA Pharma Inc. This filing is an amendment to the Schedule 13D, reflecting these changes.